Dimethyl Fumarate Versus Teriflunomide for Relapsing MS : co

Time to confirmed disability worsening was longer in patients who received dimethyl fumarate, compared with those who received teriflunomide, in an analysis of real-world data.

Related Keywords

United States , Switzerland , American , Swiss , Anthonyt Reder , , University Of Chicago , Research In Multiple Sclerosis , University Of Basel , European Committee For Treatment , European Committee , Multiple Sclerosis , Swiss Federation , Common Tasks , Health Insurance , Expanded Disability Status Scale , Medscape Medical , African American , Multiple Sclerosis Ms , Us , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Relapsing Remitting Multiple Sclerosis , Arms , Ultiple Sclerosis Relapsing Remitting , Europe , European ,